Researchers identify mutation that causes resistance to venetoclax in CLL patients

Bookmark and Share
Published: 6 Dec 2018
Views: 484
Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Dr Piers Blombery gives a press conference at ASH 2018 about the identification of a genetic mutation in BLC2 protein that causes resistance to the targeted drug venetoclax in patients with chronic lymphocyctic leukaemia (CLL).

Watch his interview with ecancer here.

Read more about this work here.